Guard Therapeutics International AB Market Cap ($3.19 Million)
Market Cap & Net Worth: Guard Therapeutics International AB (GUARD)
Guard Therapeutics International AB market cap. Guard Therapeutics International AB (ST:GUARD) has a market capitalization of $3.19 Million (Skr29.61 Million) as of November 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #29362 globally and #661 in its home market, demonstrating a 10.54% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Guard Therapeutics International AB's stock price Skr1.47 by its total outstanding shares 20167631 (20.17 Million). Also see GUARD cash generation efficiency for how efficiently the company converts equity into cash flow.
Guard Therapeutics International AB Market Cap History (2015–2026)
Guard Therapeutics International AB market cap history from 2015 to 2026. Data shows change from $5.39 Billion to $3.19 Million (-50.51% CAGR). Check GUARD live share price for real-time trading data and today's change.
Index Memberships
Guard Therapeutics International AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$15.35 Billion | 0.02% | #208 of 281 |
Weight: Guard Therapeutics International AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Guard Therapeutics International AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Guard Therapeutics International AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Guard Therapeutics International AB (GUARD) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of GUARD by Market Capitalization
Companies near Guard Therapeutics International AB in the global market cap rankings as of November 4, 2026. Also see GUARD current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Guard Therapeutics International AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Guard Therapeutics International AB (2015–2026)
Market capitalization of Guard Therapeutics International AB from 2015 to today. Between 2015 and today, Guard Therapeutics International AB's market cap moved from $5.39 Billion to $ 3.19 Million, with a yearly change of -50.51%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr3.19 Million | -0.14% |
| 2025 | Skr3.19 Million | -92.38% |
| 2024 | Skr41.89 Million | -46.09% |
| 2023 | Skr77.70 Million | -10.05% |
| 2022 | Skr86.38 Million | -39.61% |
| 2021 | Skr143.03 Million | +1.38% |
| 2020 | Skr141.07 Million | +26.69% |
| 2019 | Skr111.35 Million | +71.77% |
| 2018 | Skr64.83 Million | -88.51% |
| 2017 | Skr564.30 Million | -74.77% |
| 2016 | Skr2.24 Billion | -58.52% |
| 2015 | Skr5.39 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Guard Therapeutics International AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.19 Million USD |
| MoneyControl | $3.19 Million USD |
| MarketWatch | $3.19 Million USD |
| marketcap.company | $3.19 Million USD |
| Reuters | $3.19 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Guard Therapeutics International AB
Guard Therapeutics International AB (publ), a clinical-stage biotechnology company, identifies and develops medicines to treat kidney diseases in Sweden. Its pipeline products include RMC-035, an intact therapeutic A1M protein, that is in Phase 2b clinical trial for kidney protection with open-heart surgery; in Phase 2a clinical trial for kidney transplantation; and is in preclinical trial to tre… Read more